Vanguard Group
EVFM

Vanguard Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Vanguard Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,304,514
Closed -$1.47M – 4663
2022
Q2 		$1.47M Buy
1,304,514
+876,564
+205% +$1.45M ﹤0.01% 3945
2022
Q1 		$2.18M Sell
427,950
-29,448
-6% -$185K ﹤0.01% 3920
2021
Q4 		$2.58M Sell
457,398
-9,926
-2% -$84.4K ﹤0.01% 3947
2021
Q3 		$5.18M Hold
467,324
– – ﹤0.01% 3635
2021
Q2 		$7.92M Buy
467,324
+189,672
+68% +$3.6M ﹤0.01% 3331
2021
Q1 		$7.29M Buy
277,652
+37,886
+16% +$1.72M ﹤0.01% 3333
2020
Q4 		$8.67M Buy
239,766
+8,465
+4% +$306K ﹤0.01% 3065
2020
Q3 		$8.19M Buy
231,301
+61,874
+37% +$2.69M ﹤0.01% 2883
2020
Q2 		$7.19M Buy
169,427
+127,832
+307% +$8.62M ﹤0.01% 2918
2020
Q1 		$3.32M Buy
41,595
+13,954
+50% +$1.12M ﹤0.01% 3150
2019
Q4 		$2.56M Sell
27,641
-213
-0.8% -$18K ﹤0.01% 3376
2019
Q3 		$2.1M Sell
27,854
-16,019
-37% -$1.23M ﹤0.01% 3433
2019
Q2 		$4.37M Buy
43,873
+23,627
+117% +$1.83M ﹤0.01% 3215
2019
Q1 		$1.06M Buy
20,246
+1,950
+11% +$106K ﹤0.01% 3614
2018
Q4 		$1.15M Buy
18,296
+3,826
+26% +$211K ﹤0.01% 3528
2018
Q3 		$879K Buy
+14,470
New +$627K ﹤0.01% 3749
2018
Q1 		– Sell
-20
Closed -$4K – 4106
2017
Q4 		$4K Sell
20
-1,314
-99% -$148K ﹤0.01% 4059
2017
Q3 		$55K Sell
1,334
-314
-19% -$12.1K ﹤0.01% 4025
2017
Q2 		$80K Buy
1,648
+483
+41% +$84.6K ﹤0.01% 4001
2017
Q1 		$168K Buy
1,165
+357
+44% +$46.3K ﹤0.01% 3932
2016
Q4 		$81K Sell
808
-10
-1% -$1.04K ﹤0.01% 3992
2016
Q3 		$82K Buy
818
+138
+20% +$12.6K ﹤0.01% 3998
2016
Q2 		$60K Hold
680
– – ﹤0.01% 4070
2016
Q1 		$37K Sell
680
-1,352
-67% -$105K ﹤0.01% 4097
2015
Q4 		$255K Buy
2,032
+777
+62% +$512K ﹤0.01% 3977
2015
Q3 		$912K Buy
1,255
+401
+47% +$431K ﹤0.01% 3658
2015
Q2 		$691K Buy
854
+297
+53% +$191K ﹤0.01% 3771
2015
Q1 		$411K Buy
557
+1
+0.2% +$639 ﹤0.01% 3878
2014
Q4 		$374K Buy
+556
New +$420K ﹤0.01% 3803

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Vanguard Group's EVFM Position: Q3 2022 in Review

Vanguard Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 1,304,514 shares — an estimated $1.47M sold.

Vanguard Group first reported a position in EVFM in Q4 2014 and held it in 29 quarters. The position peaked at $8.67M in Q4 2020. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Vanguard Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Vanguard Group sold 1,304,514 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $1.47M.
  • Vanguard Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 29 quarters.
  • Vanguard Group's Evofem Biosciences, Inc. Common Stock position peaked at $8.67M in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.